EGFR and colorectal cancer: Notably, PIK3CA mutations have been found to have a synergistic effect with mutational inactivation of PTEN in inducing drug resistance [36, 37] or in inducing poor prognosis with EGFR/KRAS comutations in nonsmall cell lung and colorectal cancer [38, 39].